Bicycle Therapeutics share price logo

Bicycle Therapeutics

NASDAQ: BCYC

Small Cap

$4.09

-0.05

(-1.21%)

Live

as on

Bicycle Therapeutics Stock Performance

as on August 21, 2026 at 2:11 am IST

  • Day's Low

    Day's High

    $4.04
    $4.12
    downward going graph

    1.22%

    Downside

    0.73%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.75
    $9.16
    downward going graph

    8.44%

    Downside

    123.94%

    Upside

    downward going graph

Bicycle Therapeutics share price movements today

Previous Close
$4.14
Open
$4.06
Volume
186.2K
Market Cap
$273.0M
Day's Low - High
$4.04 - $4.12
52 Week Low - High
$3.75 - $9.16

Bicycle Therapeutics Historical Returns

1 Month Return
-7.36 %
3 Month Return
-12.36 %
1 Year Return
-47.58 %
3 Year Return
-81.79 %
5 Year Return
-86.3 %

Bicycle Therapeutics Stock Fundamentals & Key Indicators

Check Bicycle Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$273.0M

EPS (TTM)

-2.73

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.46

Industry PE ratio

-7.283372093023256

PEG Ratio

-0.06113831850622619

EBITDA

-183.2M

Revenue (TTM)

61.2M

Profit Margin

100.00%

Return On Equity TTM

-33.22%

Bicycle Therapeutics Stock Valuation

Track how Bicycle Therapeutics P/E has moved over time to understand its valuation trends.

Bicycle Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-22.83x)

December 31, 2021

Industry (-7.28x)

December 31, 2025

Today (-2.24x)

December 31, 2025

Highest (-2.24x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -2.24x

Bicycle Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Bicycle Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$273.0M-86.3%-1.46100.00%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Bicycle Therapeutics Stock including INR - Dollar returns

The Bicycle Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Bicycle Therapeutics investment value today

Current value as on today

₹60,455

Returns

-₹39,545

(-39.55%)

Returns from Bicycle Therapeutics Stock

-₹45,027 (-45.03%)

Dollar Impact

₹5,482 (+5.48%)

Analyst Recommendation on Bicycle Therapeutics Stock

Based on 6 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'BUY' rating for Bicycle Therapeutics. Average target price of $9.5

Bicycle Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Bicycle Therapeutics.

What analysts predicted

56.95%UPSIDE

Target Price

$9.5

Current Price

$4.09

Analyzed by

6 Analysts

Target

$9.50

Bicycle Therapeutics target price $9.5, a slight upside of 56.95% compared to current price of $4.09. According to 6 analysts rating.

Indian Investors' Interest in Bicycle Therapeutics Stock

Search interest for Bicycle Therapeutics Stock has increased by 40% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:40% versus previous 30 day period

Bicycle Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
19
9
2
3
9
2
11
47
0
0
Gross Profit
19
9
-42
-52
-47
-68
11
47
0
0
Operating Income
-31
-46
-63
-67
-70
-86
-65
-24
-65
-54
EBITDA
-24
-37
-61
-51
-60
-77
-57
-17
-59
-49
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
1
2
1
1
1
1
1
1
1
Income Before Tax
-26
-39
-54
-52
-61
-79
-58
-18
-60
-50
Income Tax Expense
0
0
-3
-1
-1
0
0
1
0
0
Net Income
-26
-39
-50
-51
-60
-78
-59
-20
-60
-50
Net Profit Margin
100.00%
100.00%
-1605.83%
-1412.19%
-474.03%
-2332.50%
100.00%
100.00%
100.00%
100.00%

Bicycle Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
7
13
10
11
14
26
35
72
Gross Profit
-9
-13
-11
-22
11
14
-129
-137
72
Operating Income
-16
-21
-26
-51
-65
-116
-189
-209
-247
EBITDA
-15
-21
-25
-50
-64
-107
-169
-164
-212
Interest Expense
-
-
-
0
2
3
3
1
0
Depreciation
0
0
0
1
1
3
6
7
6
Income Before Tax
-16
-22
-30
-51
-68
-114
-179
-173
-218
Income Tax Expense
0
0
0
0
-1
-1
1
-4
0
Net Income
-16
-21
-30
-51
-66
-112
-180
-169
-218
Net Profit Margin
-476.02%
-190.93%
-85.06%
-219.05%
100.00%
100.00%
-480.13%
-390.34%
100.00%

Bicycle Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-26
-39
-51
-51
-60
-78
-59
-19
-60
-50
Operating Cash Flow
-70
-44
-39
-9
-86
-72
-71
-19
-65
-49
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
1
549
-31
0
0
0
0
0
0
0
Change in Cash
-69
504
-70
-11
-86
-71
-73
-19
-68
-49

Bicycle Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-16
-21
-30
-51
-66
-112
-180
-169
-218
Operating Cash Flow
-1
-26
-28
-17
-14
-86
-60
-164
-249
Investing Cash Flow
-1
-1
-1
-1
-2
-18
-2
-1
-2
Financing Cash Flow
57
25
58
62
320
6
250
519
0
Change in Cash
58
-4
28
43
302
-99
187
353
-251

Mutual Funds that own Bicycle Therapeutics Stock

Check out the Mutual Funds with significant holdings in Bicycle Therapeutics.

Funds
Holdings
Shares Held
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
1.462272%
739251
Principal Funds, Inc
1.020869%
516100
Old Westbury Funds Inc
0.526106%
265973
MORGAN STANLEY PATHWAY FUNDS
0.107684%
54440
MUTUAL FUND SERIES TRUST
0.074176%
37500

Global Institutional Holdings in Bicycle Therapeutics

Funds
Holdings
Felix Baker
21.53%
iShares
0.69%
Louis Moore Bacon
0.54%
Marcia Venegas
0.37%
Andrew Alkon
0.15%

Insights on Bicycle Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -60.82M → -50.33M (in $), with an average increase of 20.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, BCYC stock has moved up by 4.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 624.7% return, outperforming this stock by 706.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.6% return, outperforming this stock by 534.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 47.95M → 629.0K (in $), with an average decrease of 63.6% per quarter

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
OrganisationBicycle Therapeutics
HeadquartersPortway Building, Cambridge, United Kingdom, CB21 6GS
IndustryBiotechnology
CEODr. Kevin Lee M.B.A., Ph.D.
E-voting on sharesClick here to vote

Key Management of Bicycle Therapeutics

Name

Title

Dr. Kevin Lee M.B.A., Ph.D.

CEO & Executive Director

Dr. Michael Skynner B.sc. Ph.d., Ph.D.

Chief Scientific Officer

Dr. Jennifer Perry Pharm.D.

Chief Operating Officer

Dr. Phil Jeffrey

Senior VP of Pre-Clinical Development

Dr. Michael Charles-Ferguson Hannay

Chief Product & Supply Chain Officer

Mr. Alistair Milnes

Chief Corporate Development Officer

Dr. Christian Heinis

Scientific Founder

Mr. Travis Thompson

Chief Financial Officer

Ms. Stephanie Yao

Senior Vice President of Investor Relations and Corporate Communications

Mr. Zafar Qadir

Chief Legal Officer & General Counsel

FAQs

What is Bicycle Therapeutics share price today?

Bicycle Therapeutics share price today is $4.09 as on . Bicycle Therapeutics share today touched a day high of $4.12 and a low of $4.04.

What is the 52 week high and 52 week low for Bicycle Therapeutics share?

Bicycle Therapeutics share touched a 52 week high of $9.16 on and a 52 week low of $3.75 on . Bicycle Therapeutics stock price today i.e. is trending at $4.09,which is 55.35% down from its 52 week high and 9.21% up from its 52 week low.

What is Bicycle Therapeutics's market capitalisation today?

Bicycle Therapeutics market capitalisation is $0.00T as on .

How to invest in Bicycle Therapeutics Stock (BCYC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Bicycle Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bicycle Therapeutics Shares that will get you 0.3667 shares as per Bicycle Therapeutics share price of $4.09 per share as on August 20, 2026 at 8:41 pm IST.

What is the minimum amount required to buy Bicycle Therapeutics Stock (BCYC) from India?

Indian investors can start investing in Bicycle Therapeutics (BCYC) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in Bicycle Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Bicycle Therapeutics share’s latest price of $4.09 as on August 20, 2026 at 8:41 pm IST, you will get 2.4450 shares of Bicycle Therapeutics. Learn more about fractional shares .

What are the returns that Bicycle Therapeutics has given to Indian investors in the last 5 years?

Bicycle Therapeutics stock has given -86.3% share price returns and 28.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?